RFK Jr., Dr. Oz to unveil push for lower drug prices

Trump, RFK Jr. & Dr. Oz do their best to put lipstick on their pig

You may have seen this jaw-dropping nonsense yesterday, but if you didn’t, here it is again: (sigh) OK, where to begin. Well, for starters, no, KFF (formerly the Kaiser Family Foundation) has not "retracted" their 115% increase estimate (actually...

Biden’s law sets Trump up for success in negotiating cheaper Medicare drug prices

WASHINGTON — The Trump administration is expected to announce the results of the second round of Medicare drug-price negotiations soon.  They’ll be closely watched for two big reasons: Medicare is negotiating the price of the blockbuster diabetes and weight-loss drug semaglutide, sold under the brands Ozempic and Wegovy. And Trump has bragged that he’ll strike better deals than Biden’s team, even as he’s criticized the law and weakened it by exe…

RFK Jr. announces bold plan to lower drug prices and save Americans money on healthcare

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announces bold new plan to lower drug prices across the United States. The initiative aims to make life-saving medications more affordable and reduce healthcare costs for millions of Americans.

LIVE NOW: Kennedy, Makary, and Oz to Announce Major Actions to Lower Drug Costs

Health Secretary Robert F. Kennedy Jr., Food and Drug Administration Commissioner Marty Makary, and Centers for Medicare & Medicaid Services Administrator Mehmet Oz announce major actions to lower drug costs, in Washington at 1 p.m. ET on Oct. 29. ...

RFK Jr., Dr. Oz to unveil push for lower drug prices

WASHINGTON (NewsNation) — White House health leaders Robert F. Kennedy Jr. and Dr. Mehmet Oz are expected to announce a plan to lower drug prices Wednesday. In May, President Donald Trump signed an executive order aimed at lowering the cost of prescription drugs by implementing a "most favored nation" policy that caps the prices Americans pay based on those charged in other countries. Texas AG Paxton sues Tylenol makers over alleged link to…

FDA aims to speed up biosimilar development and lower drug costs

WASHINGTON — The U.S. Food and Drug Administration (FDA) has announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.In a new draft guidance, the FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing. The agency through a separate initiative also plans to make…